Evening News|Hua Medicine’s Class 1 Innovative Drug Dopagliflozin Tablets Approved for Marketing

1.Nature Microbiology: Global Microbiologists Unite to Create New Naming System

In a new study published in Nature Microbiology, an international team of researchers from the Universities of Georgia and Pretoria has established a The new system, called SeqCode, can help researchers in the field of microbiology classify and name a large number of prokaryotes that have been identified but not yet cultivated. This system was established to combine the field of microbiology and laboratory research to reflect significant advances in environmental genomics by providing formal naming of most identified but unnamed prokaryotic pathways. (China Biotechnology Network)

2, Hua Medicine’s Class 1 innovative drug Dopagliflozin Tablets was approved for marketing

On October 8, 2022, the State Drug Administration approved the Class 1 innovative drug Dopagliflozin Tablets (trade name: Huatang) declared by Hua Medicine Technology (Shanghai) Co., Ltd. Ning) listed. This medicine is indicated to improve glycemic control in adults with type 2 diabetes. (Hua Medicine)

3.Lilly’s highly selective RET inhibitor sabrutinib was approved in China, benefiting patients with RET-driven lung and thyroid cancer strong>

Recently, Eli Lilly announced that its highly selective RET inhibitor sabrutinib (40mg & 80mg capsules) has been approved by the National Medical Products Administration (NMPA) for the treatment of transfection Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive RET gene fusion, adults with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy, and children 12 years of age and older , and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer (TC) requiring systemic therapy and who are refractory to radioactive iodine (if radioactive iodine is available). This approval in China is based on data from the global study LIBRETTO-001 and the Chinese population data from the LIBRETTO-321 study. (Eli Lilly)

4.Almost $600 million! Boehringer Ingelheim and Surrozen collaborate to develop new drug for retinal diseases

On October 6, 2022, Surrozen announced that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413, a drug for the treatment of retinal diseases. Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for various indications, including retinal diseases. Surrozen will receive an upfront payment of $12.5 million, and Surrozen will also be eligible to receive up to $586.5 million in successful development, regulatory and commercial milestone payments and mid- to low-double-digit sales royalties.

SZN-413 is a humanized bispecific antibody developed on Surrozen’s proprietary SWAP platform that simultaneously targets the FZD4 receptor and LDL receptor-related protein 5 (LRP5), a novel FZD4 agonist. Preclinical data show that SZN-413 can effectively stimulate the activation of the Wnt signaling pathway in the eye, thereby promoting normal retinal vascular regeneration, inhibiting pathological vascular growth and reducing vascular leakage. So the therapy doesn’t just inhibit retinopathy, it has the potential to regenerate healthy eye tissue, potentially reversing disease progression in patients. (Medicine Rubik’s Cube)